Lipoprotein Lipase and PPAR Alpha Gene Polymorphisms, Increased Very-Low-Density Lipoprotein Levels, and Decreased High-Density Lipoprotein Levels as Risk Markers for the Development of Visceral Leishmaniasis byLeishmania infantum
Open Access
- 1 January 2014
- journal article
- research article
- Published by Wiley in Mediators of Inflammation
- Vol. 2014, 1-10
Abstract
In visceral leishmaniasis (VL) endemic areas, a minority of infected individuals progress to disease since most of them develop protective immunity. Therefore, we investigated the risk markers of VL within nonimmune sector. Analyzing infected symptomatic and, asymptomatic, and noninfected individuals, VL patients presented with reduced high-density lipoprotein cholesterol (HDL-C), elevated triacylglycerol (TAG), and elevated very-low-density lipoprotein cholesterol (VLDL-C) levels. A polymorphism analysis of the lipoprotein lipase (LPL) gene using HindIII restriction digestion (N= 156 samples) (H+ = the presence and H− = the absence of mutation) revealed an increased adjusted odds ratio (OR) of VL versus noninfected individuals when the H+/H+ was compared with the H−/H− genotype (OR = 21.3; 95% CI = 2.32–3335.3;P= 0.003). The H+/H+ genotype and the H+ allele were associated with elevated VLDL-C and TAG levels (P< 0.05) and reduced HDL-C levels (P< 0.05). An analysis of the L162V polymorphism in the peroxisome proliferator-activated receptor alpha (PPARα) gene (n= 248) revealed an increased adjusted OR when the Leu/Val was compared with the Leu/Leu genotype (OR = 8.77; 95% CI = 1.41–78.70;P= 0.014). High TAG (P= 0.021) and VLDL-C (P= 0.023) levels were associated with susceptibility to VL, whereas low HDL (P= 0.006) levels with resistance to infection. The mutated LPL and the PPARα Leu/Val genotypes may be considered risk markers for the development of VL.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (154581/2006-2, 06/60006-9, LIM/38 HC-FMUSP)
- Fundação de Amparo à Pesquisa do Estado de São Paulo (154581/2006-2, 06/60006-9, LIM/38 HC-FMUSP)
- Laboratório de Investigação Médica (154581/2006-2, 06/60006-9, LIM/38 HC-FMUSP)
This publication has 48 references indexed in Scilit:
- Association of interleukin-18 gene variants with susceptibility to visceral leishmaniasis in Iranian populationMolecular Biology Reports, 2012
- Transcriptomic Signature of Leishmania Infected Mice Macrophages: A Metabolic Point of ViewPLOS Neglected Tropical Diseases, 2012
- Genetic and functional evaluation of the role of CXCR1 and CXCR2 in susceptibility to visceral leishmaniasis in north-east IndiaBMC Medical Genetics, 2011
- No evidence for association between SLC11A1and visceral leishmaniasis in IndiaBMC Medical Genetics, 2011
- Genetics and visceral leishmaniasis: of mice and manParasite Immunology, 2009
- Transcriptional signatures of BALB/c mouse macrophages housing multiplying Leishmania amazonensis amastigotesBMC Genomics, 2009
- Hypocholesterolemia and increased triglyceride in pediatric visceral leishmaniasisClinica Chimica Acta, 2007
- Relationship between lipoprotein lipase and peroxisome proliferator-activated receptor-α expression in rat liver during developmentJournal of Physiology and Biochemistry, 2006
- The Potential Role of Mannan‐Binding Lectin in the Clearance of Self‐Components Including Immune ComplexesScandinavian Journal of Immunology, 2004
- A Major Susceptibility Locus on Chromosome 22q12 Plays a Critical Role in the Control of Kala-AzarThe American Journal of Human Genetics, 2003